折价发行，恒瑞医药港股股价首日开盘涨三成

Group 1 - The core viewpoint of the news is that Heng Rui Pharmaceutical successfully completed its IPO in Hong Kong, with a final issue price of HKD 44.05 per share, representing a discount of nearly 27% compared to its A-share closing price on May 22 [1][2] - The IPO raised a total of HKD 98.9 billion, with a net amount of HKD 97.47 billion after deducting listing expenses, which will be used for R&D and expanding production facilities [2] - Heng Rui Pharmaceutical's stock price surged approximately 30% on its debut in Hong Kong, while its A-share price experienced a slight decline [1][2] Group 2 - Heng Rui Pharmaceutical is competing with BeiGene for the title of "innovative drug leader" in the A-share market, but it has not yet received approval for any innovative drugs overseas [3] - The company has engaged in nine licensing agreements over the past three years, generating approximately USD 14 billion in total transaction value, which has become a significant source of revenue [3] - The company's strategy includes enhancing its international presence through the Hong Kong listing, aiming for breakthroughs in overseas markets [4]